anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention relates to a medicine for treating esophageal cancer. The medicine is characterized by comprising the following active ingredients by weight: 50-200 g of chicken&#39;s gizzard-membrane, 2-8 g of costus root, 2-8 g of flos caryophylli, 1-7 g of agalloch and 5-20g of fructus jujubae; costusroot, flos caryophylli, agalloch and fructus jujubae are dry, the chicken&#39;s gizzard-membrane is fresh. A preparation method of the medicine comprises the following steps: removing contents in the chicken guts, wrapping the chicken guts externally with a plurality of layers of wet paper, sealing with mud, barbecuing with charcoal until the interior is moderately burnt, removing mud and paper ash; and then grinding all active ingredients except for the fructus jujubae, evenly mixing, adding the fructus jujubae to produce water pills. The medicine has the beneficial effects of eliminating stagnated food to destroy intestinal worms, tonifying middle-Jiao and Qi, invigorating spleen to promote digestion, regulating yin and yang, and has an obvious treatment effect when being used for treating esophageal cancer. After being used for treating 116 cases, the total effective rate achieves 99.1%. Furthermore, by adopting a method of sucking in the mouth, the medicine is convenient to take.
An eyelid scrub composition comprising polyhexamethylene biguanide (PHMB), 1,2-hexanediol, 1,2-octanediol, and a pH stabilizing surfactant solution present in an amount effective to control the pH level of the composition between 5.5 and 7.5. The composition can further comprise moisturizers and foam stabilizers. The composition can be combined with a fabric pad for use as an eyelid scrub, where the fabric pad is pre-moistened with the composition and packaged for use. The composition may be applied to the eyelid scrub and rubbed to induce foaming. The composition is produced by preparing a modified Ringer&#39;s solution and adding 1,2-hexanediol, 1,2-octanediol, and an effective amount of one or more pH stabilizing surfactants. The mixture is then heated and allowed to cool before polyhexamethylene biguanide is added.
Infusion soln. and flushing liquids for the treatment of cerebral oedemas consist of hypertonic or isotonic aq. solns contg. suuccanate, fructose-diphosphate and glycero-3-phosphate and pref. &gt;=1 of CDF-choline, UDF-glucose, glycerol, saccharides and/or physiologically compatible inorganic salts. The water-content of the oedema is reduced and in addition the material exchange of the oedematous tissue is simultaneously intensified.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an information management system, information management method, and program suitable for managing information stored on a patient&#39;s registration card possessed by a patient of a hospital or the like.  &lt;P&gt;SOLUTION: A server 1 of the information management system receives information stored in a tag device 6 via an antenna 5, and stores it in a database 2. An input/output terminal device 4 displays the information, and receives additional information associated with the information. The server 1 transmits the additional information to the tag device 6. The tag device 6 further displays the additional information in addition to the information.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a technique for keeping the initial state of the skin finished with a makeup cosmetic product for a long period.  &lt;P&gt;SOLUTION: The foundation cosmetic product contains (1) an aluminum-zinc intercalate pillared clay and (2) a clay mineral modified with an organic material. The clay mineral modified with an organic material is preferably hectorite modified with dimethyl distearyl ammonium chloride. The cosmetic product preferably contains a polyether-modified methylsiloxane preferably having a crosslinked structure. The cosmetic product is preferably a foundation cosmetic, more preferably a foundation cosmetic for a hydrophobic makeup cosmetic product.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE: To obtain an agent and food containing chlorella as an active compo nent, capable of inhibiting the absorption of lipid contained in a food into a body and at the same time stimulating the extrusion of lipid absorbed in a body, and accordingly enabling the prevention of hypercholestrerolemia and obesity. CONSTITUTION: These are a liquid absorption inhibiting and extrusion stimulating agent containing chlorella as an active component and a high fat food containing chlorella. The chlorella is preferably Chlorella regularis, Chlorella vulugaris, Chlorella pyrenoidosa, etc., which are easily available and excellent in safety. Further, the agent is preferably taken orally before, during or after a meal, and it is preferably administered at a deily dose of about 4-8g for an adult in a usual case. Furthermore, the mixing of the agent to a high fat food having a fat content of about &gt;=10% (e.g. hamburg or ice cream) allows a heart disease patient, etc., to enjoy the high fat food without worrying about the troubles of the excess taking of fat.
The preparation of technetium-99m with 6-fluoroquinolones can be a diagnostic imaging agent aiming at the differential diagnosis between infection and sterile inflammation.The present invention relates to the preparation of the standardized technetium-99m cold kit through which the short, simple and safe preparation of radiopharmaceuticals in a single step will be possible by the simple reconstitution of the cold kit&#39;s content with injectable Sodium Pertechnetate-99mTc solution.The cold kit contains all the necessary ingredients for this purpose in a stable in vitro formulation. The preparation method is particularly easy-to-use, effective and pharmaceutically appropriate, it allows though the storing of the standardized kits for a sufficient period of time. The content of the kits for the preparation of the radiopharmaceuticals has the form of lyophilized dry powder. It has to be sterile and pyrogen free. The preparation method of the cold kit includes the mixing of the necessary ingredients under aseptic conditions. 1 mg 6-fluoroquinolone, 0.3 mg stannous chloride (SnCl2) and some quantity of an antioxidant (ascorbic acid) are contained per vial. The final solution is lyophilized and the sealing of the vials under vacuum follows. The standardized kit is kept in the refrigerator (2-8 C). The reconstitution/ dissolution of the cold kit is carried out only by the addition of injectable Sodium Pertechnetate-99mTc solution (radioactive 99mTc-technetium labeling). The radioactive solution can be administrated to patients up to 5 hours after the labeling according to the principles of protection against radiation.
&lt;P&gt;PROBLEM TO BE SOLVED: To quickly transfer photograph order information in photographing a medical image during a doctor&#39;s round visit and to prevent the duplication of data.  &lt;P&gt;SOLUTION: In this medical image photography system 100, a PDA 4a and a PDA 4b transmit/receive an ID number and a password mutually via a short-range radio communication for authorizing each other according to the received ID number and password. After the authorization, the PDA 4a transmits selected photograph order information to the PDA 4b. On receipt of the photograph order information from the PDA4a, the PDA 4b transmits the photograph order information receipt notification to the PDA 4a and stores the received photograph order information in a storage part 46. On receipt of the photograph order information receipt notification, the PDA 4a deletes the photograph order information transmitted from the storage part 46.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
System and method for generating and managing tasks relating to patient office visits with healthcare providers. A priority is assigned to each task based on a desired patient experience or provider efficiency. A set of prioritized tasks is generated, assigned to a user for completion, and dynamically displayed on an interactive user interface to enable the assigned user to access and manage the prioritized tasks and accept user responses for completing the tasks. The user responses are monitored and processed to detect the timing, content or lack of user responses. The related tasks of a workflow may be assigned to users across different provider groups, and their cumulative responses monitored and synchronized for timely completion. At regular or varying time intervals, which intervals can be adjusted based on a user&#39;s response history or other factors, the user receives a continuously updated and prioritized list of tasks to enable more efficient completion of the tasks. The system is configured to learn over time which priorities, presentation forms and assigned users best achieve a timely completion of such tasks.
NEW MATERIAL:The compound of formula I (R is -CH2-S-CH3, -CH2-CH2-CH3 or group of formula II). EXAMPLE:The compound of formula III. USE:An anticarpaine compound. It exhibits strong enzymeinhibiting activity against carpaine, and little inhibiting activity to serine protease. PREPARATION:The objective compound of formula I can be prepared by suspending the ester of formula IV (R&#39; is methyl or ethyl) in a tert-alcohol, adding a reducing agent such as sodium borohydride, adding anhydrous methanol to the mixture under refluxing in an inert gas atmosphere, and oxidizing the resultant alcohol of formula V with sulfur trioxide-pyridine complex in dimethyl sulfoxide. The starting compound of formula IV is synthesized by conventional peptide synthesis using corresponding amino acids or peptides.
FIELD: medicine, phytotherapy, pharmacy. SUBSTANCE: invention relates to parapharmaceutical industry producing preparations of curative and prophylactic designation. The preparation comprises Saint-John&#39;s-wort herb processing product, magnesium asparaginate as a magnesium compound, dry concentrate of rosewort extract, dry concentrate of coffee decoction, flower pollen, cacao, citric acid, starch, wheat bran, calcium stearate and sugar. The supplement reduces or eliminates nervopsychic stress, fear and anxiety. EFFECT: valuable medicinal properties of supplement. 1 tbl, 4 ex
PURPOSE:To obtain an extracted raw material without lowering saponin content, by contacting raw material of AMACHAZURU (Gynostemma pentaphyllum) selected from raw stalks and leaves, etc., of AMACHAZURU with a basic or acidic aqueous solution. CONSTITUTION:Raw material of AMACHAZURU selected from raw stalks, leaves or their cut product of AMACHAZURU is made to contact with an aqueous solution of a base or acid for 0.5-24hr. The pH of the basic aqueous solution is &gt;=10 (e.g. NaOH) and that of the acidic aqueous solution is &lt;=3 (e.g. 0.1-2N HCl). The temperature of the aqueous solution is between the freezing point and 40 deg.C, preferably 0-35 deg.C. The aqueous solution is used at least in an amount to be sufficient to wet the whole surface of the raw material, i.e. 5-200ml per 1g of the raw material. A raw material of AMACHAZURU containing inactivated saponin-hydrolyzing enzyme can be produced by the contacting treatment and the raw material can be used as a raw material for the production of an extract.
PURPOSE:To provide the titled composition for external use, effective remarkably to the remedy of chapped skin, spots, freckles, pimples, etc., by using OREN (rhizoma of Coptis japonica MAKINO var. dissecta NAKAI) which is an orally administrable crude drug, as an essential active component of a cosmetic for continuous use. CONSTITUTION:Powder of OREN used as an oral drug such as a digestive, a herb medicine, a crude drug preparation, etc., or its extract with water or aqueous alcohol (e.g. an aqueous extract obtained by extracting with 30% ethanol at 15-25 deg.C: 1pt. of the extract can be obtained from 5pts. of the OREN), is added to a cosmetic in an amount of &gt;=0.005wt%, preferably about 2wt%. The compounded composition can be used in the form of cream, beauty wash, baby powder, soap, etc. by conventional method.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a body fat combustion promotion composition that can be safely ingested and has a high body fat combustion effect, and provide a food and a medicine each containing the body fat combustion promotion composition.  &lt;P&gt;SOLUTION: The body fat combustion promotion composition contains GABA (γ-aminobutyric acid) to ameliorate alimentary lipemia and non-alimentary lipemia. In addition, this body fat combustion promotion composition has the effects to promote the combustion of cumulated fat, alimentary fat and abdominal fat. The body fat combustion promotion composition contains GABA as as active ingredient. The food and the medicine containing this body fat combustion promotion composition can be ingested safely and smoothly.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
Methods for controlling surface topography and binding reactivity in functionalized lipid layers, including in the form of liposomes, using pH-dependent processes. During direct cell-to-cell communication, lipids on the extracellular side of plasma membranes reorganize, and membrane associated communication-related molecules co-localize. At co-localization sites, sometimes identified as rafts, the local cell surface topography and reactivity are altered. Integration of these processes on nanometer-sized lipid vesicles used as drug delivery carriers would precisely control their interactions with diseased cells minimizing toxicities. Included are pH-dependent processes on functionalized lipid bilayers demonstrating reversible sharp changes in binding reactivity within a narrow pH window. Cholesterol enables tuning of the membrane reorganization to occur at pH values not necessarily close to the reported pKa&#39;s of the constituent titratable lipids. One illustrative function of the invention is to use liposomes to deliver bioactive agents to cancer or tumor cells and compositions of specific lipids that form liposomes to deliver a biologically active agent.
The present invention provides an improved method for treating blood to remove foreign substances such as immune complexes and free antigen. This is advantageously accomplished by separating a portion of a patient&#39;s blood as plasma, and acidifying the plasma to a pH below about 3.1 in order to cause the immune complexes to dissociate into antigen and antibody. After removing the antigen, the plasma is returned to the patient. Preferably, the patient&#39;s blood is substantially diluted prior to plasma separation, thereby substantially increasing the clearance rate of the plasma separator device and also washing off antigens bound to cellular blood components. Also, it is preferred that the plasma fraction is further diluted during the acidification step. Subsequent removal of excess fluid will cause substantial removal of free antigen. In a presently preferred process, the excess fluid volume is reduced by use of an ultrafiltration device capable of passing antigen, but not larger protein constituents of plasma. The resultant plasma solution is advantageously subjected to dialysis to simultaneously remove remaining antigen and to raise the pH back to a physiological level.
An apparatus and method for measuring the key elements of human primary health is disclosed. The apparatus is in the form of a medical diagnostics unit capable of measuring Electrocardiogram (ECG), height, weight, body mass index (BMI), body temperature, hearing efficiency, lung function, pulse, blood oxygen levels, blood pressure, urology and vision testing. The medical diagnostics unit includes an enclosure with a data card and/or fingerprint entry. The enclosure includes medical measuring devices which allow a patient to follow instructions on a touch screen visual display unit to conduct the desired tests and obtain the patient&#39;s health information. This information is stored locally as well as being transmitted to a doctor for review and evaluation. The automated medical diagnostics unit reduces the staffing requirements to obtain a patient&#39;s basic health information.
2-Ethinyl butanol-2 is prepared by reacting methyl ethyl ketone with acetylene in the presence of an alkaline condensing agent such as sodium, sodamide, potassamide, potassium t.-amylate or potassium hydroxide.  In the example, acetylene is passed through a suspension of potassium hydroxide in dry ether, the ketone is added and the passage of acetylene continued for 3 hours.  With sodium as condensing agent, the reaction is carried out in the presence of liquid ammonia.  Esters of acetic, propionic, butyric, benzoic, salicylic, phthalic, hexahydrophthalic, maleic, malic, tartaric, citric and succinic acids are prepared by reacting 2-ethinyl butanol-2 with the appropriate anhydride or chloride of the acid, if desired in the presence of a catalyst.  In the case of polybasic acids, both the acid esters and the neutral esters may be prepared. Described is the preparation of (a) 2-ethinyl-2-acetoxybutane; (b) 2-ethinyl-2-propionoxy butane; (c) 2-ethinyl-2-butyroxy butane; (d) 2-ethinyl-2-butyl hydrogen phthalate; and (e) 2-ethinyl-2-butyl benzoate.  The carbinols and their esters are used in pharmaceutical preparations (see Group VI).ALSO:Physiologically active preparations contain as an active ingredient a compound of the general formula &lt;FORM:0736993/VI/1&gt; wherein X is hydrogen or an acyl group, together with a non-toxic carrier, namely an edible vegetable or mineral oil, a polyoxyethylene glycol, or an inert solid carrier such as heavy magnesium oxide, magnesium carbonate, certain diatomaceous earths, or waxes.  The acyl covers both aliphatic and aromatic carboxylic and sulphonic radicals.  Specified are the residues of acetic, propionic, butyric, benzoic, salicylic, phthalic, hexahydrophthalic, maleic, malic, tartaric, citric and succinic acids.  Such preparations are administered orally, parenterally or as suppositories.  Injections take the form of aqueous or oily solutions or suspensions containing dispersing agents such as polyethylene glycols.  Oral medicaments are (a) soft gelatin capsules in which the carbinol is dissolved in oil such as peanut, sesame or corn oil; (b) hard gelatin capsules, in which the carbinol is absorbed on an inert absorbent, e.g. magnesium oxide or carbonate, with or without the further addition of oil; (c) tablets having a coating of resin; (d) elixir, in which the vehicle is an aqueous solution of propylene glycol or ethyl alcohol, glycerin and sucrose; (e) emulsion of oil, e.g. peanut, emulsifier, e.g. polyethylene glycol monostearate, and thickener, e.g. acacia, gelatin, dextrin, pectin, sodium alginate or agar agar. Suppositories have a basis of (a) white wax and cocoa butter, or (b) carbowax.  Described is the preparation of (a) methyl ethyl ethinyl carbinol; (b) 2-ethinyl-2-acetoxybutane; (c) 2-ethinyl-2-propionony butane; (d) 2 - ethinyl - 2 - butyroxy butane; (e) 2 - ethinyl - 2 - butyl hydrogen phthalate and 2-ethinyl-2-butyl benzoate (see Group IV (b)).
The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISA&lt;SUB&gt;TX&lt;/SUB&gt;247, and derivatives thereof. Mixtures of ISA&lt;SUB&gt;TX&lt;/SUB&gt;247 isomers exhibit a combination of enhanced potency and reduced toxicity over the naturally occurring and presently known cyclosporins. ISA&lt;SUB&gt;TX&lt;/SUB&gt;247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. The ratio of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)-isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight of the mixture.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a microchip device for controlling the exposure of a secondary device.  &lt;P&gt;SOLUTION: The microchip device includes a substrate. The substrate has a plurality of reservoirs. The plurality of reservoirs contains the secondary device, and reactive components or a combination thereof. At least one barrier layer covers the each reservoir to protect a content of the each reservoir from one or more environmental components existing in an outside of the reservoir. The barrier layer can be selectively decomposed or permeable, and a separated contents is thereby exposed to the one or more environmental components. The secondary device preferably includes a sensor or sensing component (for example, a biosensor, or a photodetecting or image generating device (for example, optical fiber)). A catalysts and a reagent are mentioned as preferable reactive components, and may be immobilized in the reservoir.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES Abstract The novel positively charged pro-drugs of NSAIAs in the general formulas (1, 2a, 2b, 2c, or 2d) &#34;Structure 1, 2a, 2b, 2c, or 2d&#34; were designed and synthesized. The compounds of the general formulas (1, 2a, 2b, 2c, or 2d) &#34;Structure 1, 2a, 2b, 2c, or 2d&#34; indicated above can be prepared from metal salts, organic base salts, or immobilized base salts of NSAIAs with suitable halide compounds. The positively charged amino groups in the pro-drugs in this invention largely increase the solubility of the drugs in water and will bond to the negative charge on the phosphate head group of membrane. Thus, the local concentration of the outside of the membrane or skin will be very high and will facilitate the passage of these pro-drugs from a region of high concentration to a region of low concentration. This bonding will disturb the membrane a little bit and may make some room for the lipophilic portion of the pro-drug. When the molecules of membrane move, the membrane may &#34;crack&#34; a little bit due to the bonding of the pro-drug. This will let the pro-drug insert into the membrane. At pH 7.4, only about 99% of the amino group is protonated. When the amino group is not protonated, the bonding between the amino group of the pro-drug and the phosphate head group of the membrane will disassociate, and the pro-drug will enter the membrane completely. When the amino group of the pro-drug flips to the other side of the membrane and thus becomes protonated, then the pro drug is pulled into the cytosol, a semi- liquid concentrated aqueous solution or suspension. These pro-drugs can be used for treating and preventing diabetes (type I or/and type II), abnormal blood glucose and lipid levels, stroke, heart attack, and other heart and vascular diseases, Alzheimer&#39;s diseases, Parkinson&#39;s diseases and other neurodegenerative diseases, psoriasis, discoid lupus erythematosus, systemic lupus erythematosus (SLE), autoimmune hepatitis, multiple sclerosis (MS), and other autoimmune diseases, amyotrophic lateral sclerosis (ALS), oculopharyngeal muscular dystrophy (OPMD), and other muscle disorders, inflamed hemorrhoids, cryptitis, other inflammatory conditions of the anorectum, and pruritus ani, prostatitis, prostatocystitis, varicose veins, autoimmune liver inflammation, autoimmune kidney inflammation, vein inflammation and other inflammations, skin cancers, breast cancer, colon rectum cancer, oral cancer, and other cancers, scars, abnormal vascular skin lesions, birthmarks, moles (nevi), skin tags, aging spots (liver spots), and other skin disorders. These pro-drugs can be administered transdermally without the help of skin penetration enhancers.